Tate & Lyle ordinary shares trade on the London Stock Exchange and may be accessed on Bloomberg under the symbol TATE LN, on the Reuter Equities 2000 Service under TATE.L and on Quotron under TATEU.EU. In the US, Tate & Lyle's ADRs trade on the NASD OTC Bulletin Board under TATYY (each ADR is equal to four ordinary shares). Tate & Lyle 6.5% Cumulative Preference Shares are traded on the London Stock Exchange under the ticker BD15.
Please refer to the latest "Total Voting Rights" release available in the "Regulatory news" section of this website).
Tate & Lyle ordinary shares can be bought and sold through a stockbroker or share dealing service. Our registrar, Equiniti, also operates a share dealing service which offers shareholders a simple way of buying or selling shares, either over the telephone, or via the internet. For more information, click here. Alternatively, you can telephone 08456 037 037. Lines are open from Monday to Friday (excluding bank holidays) between 8.00am and 4.30pm for sharedealing and until 6.00pm for enquiries.
Tate & Lyle's registrar is Equiniti. Their address is:
Click here to access Equiniti's website and online share information. For telephone enquiries please phone: 0871 384 2063 (for UK calls) or + 44 (0)121 415 7047 (for calls from overseas).
If you are registered with Equiniti's online service www.shareview.co.uk you can change your address by logging in to your Portfolio. You will require the shareholder's full name and current registered address and the shareholder reference number (both of these can be found on a share certificate, recent dividend voucher or any other correspondence from Equiniti).
If you are not registered with Shareview you will need to print off the relevant form, which you can download here. Complete it and return it to Equiniti at the address provided on the form.
You should notify Equiniti in writing, enclosing a copy of your marriage certificate or change of name deed together with your share certificate(s).
If you lose your share certificate or it has been stolen, you should inform Equiniti immediately by phoning 0871 384 2063* (for UK calls) or + 44 (0)121 415 7047 (for calls from overseas). You will then be sent a letter of indemnity, which must be completed and returned to Equiniti so that a replacement certificate can be issued. There is a charge for this service. Please note that once a letter of indemnity has been issued it cannot be reversed, even if you subsequently locate your original certificate. You may, therefore, prefer to check your records again before contacting Equiniti.
* Calls to 0871 numbers are charged at 8 pence per minute from a BT landline. Other telephone providers' costs may vary.
If you are administering an estate, you may need to transfer shares into the names of beneficiaries or sell the holding. The first step is to write to Equiniti to tell them your intended action. Equiniti will then place a temporary marker on the register to ensure that wherever possible, no further dividend payments are issued in the shareholder's name. Equniti will also send you the forms that you will need to complete.
If you wish to transfer your shares, you can transfer your holding using a stock transfer form. A Stock Transfer Form, along with instructions on how to complete the form, can be obtained by contacting Equiniti. Alternatively, you can download the form here.
ADR enquiries should be directed to The Bank of New York Mellon, which is the Depositary for Tate & Lyle American Depositary Receipts. Contact details for the Depositary can be found below:
BNY Mellon Shareowner Services
PO Box 358516
Pittsburgh, PA 15252-8516
OTCQX is the premium tier of the U.S. over-the-counter marketplace which gives non-U.S. companies a visible U.S. cross-listing without the duplicative regulatory costs required of listing on a traditional U.S. exchange.
OTCQX companies use the quality controlled OTCQX listing platform to offer investors transparent trading, superior information, and easy access through their U.S. regulated broker-dealers. The innovative OTCQX platform offers companies and their shareholder a level of marketplace services formerly available only on a U.S. exchange.
Tate & Lyle currently pays dividends twice a year: the interim, for the six months to September, is typically paid in January, and the final, for the six months to March, is typically paid at the end of July or beginning of August.
To view our dividend information and history, please , click here.
If you want to add or change a bank account or want to have your dividend paid to someone else, you will need to inform Equiniti. If you are registered with Shareview you can notify Equiniti of your changes immediately by logging into your Portfolio. If you have not yet registered, you can do so by clicking here.
Alternatively, you can click here to download a dividend instruction form. Please complete and sign the form and return to Equiniti.
On 27 May 2011, Tate & Lyle announced that shareholders will be able to participate in a DRIP. The DRIP provides shareholders with the opportunity to reinvest their dividends in Tate & Lyle PLC shares. For more information on Tate & Lyle’s DRIP, please click here
Please contact Equiniti, who can check the payment details and, if appropriate, issue another cheque. To avoid this problem, you may like to consider having your dividends paid directly into your bank or building society account.
Historical share prices can be found in the share price section of this website, where we hold data going back to 2001. If you require share prices prior to this, you should contact your own broker. Alternatively, the London Stock Exchange can provide this information.
Shareholder documents are only sent in paper format to shareholders who have elected to receive documents in this way. This approach enables the Company to reduce printing and distribution costs and its impact on the environment.
Shareholders who have not elected to receive paper copies are sent a notification whenever shareholder documents are published, to advise them how to access the documents via the Tate & Lyle website, www.tateandlyle.com. Shareholders may also choose to receive this notification via email with a link to the relevant page on the website. Shareholders who wish to receive email notification should register online at www.shareview.co.uk, using their reference number that is either on their share certificate or other correspondence.
Yes, all Tate & Lyle shareholders currently receive a Proxy Form in paper format unless they have elected to receive an email notification, which includes details of how to appoint a proxy online.
If you wish to receive e-mail notification, please register online at www.shareview.co.uk using your reference number that is either on your share certificate or other correspondence.
Please go to our Financial Calendar
and click on the "AGM" tab to view the currently scheduled AGM dates.
Tate & Lyle is the number three corn wet miller in the world and produces all of its corn-based ingredients through a wet milling process. The process begins by cleaning and steeping the shelled corn in water. The basic corn starch which makes up 57% of the corn kernel is then extracted through a grinding and separation process. This basic starch is the building block to all of our corn-based ingredients and goes through further physical or chemical modification, fermentation or refining to produce a diverse range of cereal sweeteners, starches, gums and acidulants for the food and industrial markets.
Although the starch is the most valuable component of the corn kernel for Tate & Lyle, nothing is wasted and selling on the remaining components helps manage the net cost of corn. The remaining 43% non-starch components are broken down into 22% corn gluten feed (made from the hull and fibre and used in cattle feed); 4% gluten meal (extracted from the endosperm and used in aquaculture feed and pet food; 3% corn oil – made from the germ and used by the food industry; and the remaining 14% is water.
For more information on corn wet milling and Tate & Lyle's other production processes, please click here.
You can also find out more about corn wet milling on the corn refiners association website: www.corn.org
Selling corn-based commodity products in both the USA and Europe is usually done through annual pricing rounds. These involve a series of face-to-face meetings with key customers, held over a number of months, where prices for products like high fructose corn syrup, or charges for toll production are negotiated for the next 12 months or in some cases on a multi-year basis. The majority of our commodity ingredients, both food and industrial, are sold through this mechanism, with only a small amount sold on a spot (or ad hoc) basis.
The pricing rounds are highly commercial and it is the responsibility of our sales teams to ensure that we get the best price for our products, while remaining competitive against other ingredient suppliers who may sell the same ingredient or substitute products.
In the USA, as soon as a customer order is agreed, if we do not hold actual corn in storage, we manage the risk of changing corn prices by hedging corn costs on the Chicago Mercantile Exchange (CME). This involves entering into a futures contract at the CME whenever we take an order from a customer, which means we can buy corn at a specific price at a set date in the future, allowing us to budget without considering fluctuating corn prices. CME contracts offer the opportunity to establish raw material values as quoted today for periods up to two years in advance. For more information on the latest US corn prices, please visit CME's website here.
In Europe, a smaller market for us than the USA, there is no liquid corn futures market, which means we cannot hedge the full corn price cost as we can in the USA. It is not possible to use hedging procedures to lock in the majority of by-product revenues in either Europe or the USA.
SPLENDA® Sucralose is manufactured by a multi-step patented process which starts with sugar. The process selectively replaces three hydrogen-oxygen groups on the sugar molecule with three chlorine atoms. The result is a sweetener that is approximately 600 times sweeter than sugar and has no calories.
For more information on sucralose and Tate & Lyle's other production processes, please click here.
For more information on SPLENDA® Sucralose, please visit www.sucralose.com and www.sucralose.org.
The safety of sucralose is well documented in more than 100 scientific studies conducted over a 20-year period. In addition, sucralose and, specifically, the safety data on sucralose, has been reviewed by the U.S. Food and Drug Administration (FDA) and other national regulatory agencies, as well as by international health authorities such as the World Health Organization, and found to be safe for use by all consumers, including children, pregnant women and people with diabetes.
Sucralose has been available in international markets for more than 17 years. The FDA first approved the use of sucralose as a non-nutritive sweetener in 1998 and expanded this approval in 1999. Currently, sucralose is permitted for use in over 80 countries and it has never been required to carry any safety information or warning statements on its labelling. For more information on the safety of sucralose please visit www.sucralose.org/.
Tate & Lyle operates more than 30 production facilities mainly in the Americas, Europe and South East Asia.
At 31 March 2011, Tate & Lyle employed 4,500 people across the Group.
Please go to our Financial Calendar
and click on the "results" tab to view the currently scheduled financial reporting dates.
We have two corporate brokers, Citi and Jefferies (Hoare Govett). Addresses are given below:
33 Canada Square
London E14 5LB
Jefferies (Hoare Govett)
68 Upper Thames Street
London EC4V 3BJ
Access an archive of our annual report
See our current share price, use our share price calculator, calculate the value of your share holding
Corporate and Investor Relations, Company Secretariat, Treasury, Finance
Tate & Lyle PLC
London WC2B 6AT
T: (+44) (0)20 7257 2100
F: (+44) (0)20 7257 2200
© 2014 Tate & Lyle - All rights reserved.SPLENDA® and the SPLENDA® Logo are trademarks of McNeil Nutritionals, LLC